Syndax Pharmaceuticals racks up $80 mln Series C

By Iris Dorbian — 6 months ago

Waltham, Massachusetts-based Syndax Pharmaceuticals Inc, a biopharmaceutical company focused on treating cancer, has closed $80 million in Series C funding. Fidelity Management & Research Company and Delos Capital Fund LP led the round with participation from other investors that included EcoR1 Capital, OrbiMed, Jennison Associates (on behalf of certain clients), Tavistock Life Sciences, Arrowpoint Partners, Cormorant Asset Management, BioMed Ventures, Domain Associates, MPM Capital, RusnanoMedInvest and Forward Ventures.

Continue

Nabriva Therapeutics inks $120 mln Series B

By Iris Dorbian — 10 months ago

Biotech company Nabriva Therapeutics AG has closed $120 million in Series B funding. Vivo Capital and OrbiMed led the round with participation from EcoR1 Capital, Boxer Capital of Tavistock Life Sciences, HBM, Phase4 Partners, Wellcome Trust, GLSV and Novartis Venture Fund. In addition to the funding, representatives of Vivo Capital and OrbiMed will join Nabriva’s supervisory board.

Continue

Blueprint Medicines ropes in $50 mln

By Iris Dorbian — 1 year ago

Blueprint Medicines has raised $50 million in Series C funding. Partner Fund Management led the round with participation from other investors that included Wellington Management Company, RA Capital, Tavistock Life Sciences, Perceptive Advisors, Sabby Capital, Cowen Investments, Redmile Group, Fidelity Biosciences and Third Rock Ventures. Based in Cambridge, Mass., Blueprint Medicines is a developer of kinase inhibitors for genomically defined cancers.

Continue